- Salt reduction is beneficial for people with Type 2 diabetes
- Pioglitazone raises risk of bladder cancer by 63%
- Diabetes 2015 – Care in Crisis
- Diabetic Retinopathy
- People with diabetes not offered dietary advice
- Medication errors in hospitals
- First ever mandatory care standards to improve the level of care of children and young people with diabetes
- Insulin Analogues and Cancer – A Possible Link That Needs Further Investigation
- The Safety of Insulin Analogues – should patients be concerned?
- Bellagio Report
- Health Select Committee – IDDT gives evidence
- Warnings about ‘human’ insulin from the manufactuers, Novo Nordisk and Aventis
- Zyban – Safety precautions from the Committee on Safety of Medicines
- Novo Nordisk discontinue some GM ‘human’ insulins
- IQWiG: No proof long-acting insulin analogues outperform human insulin for Type 2 diabetes
- Cochrane Review – long-acting analogues vs NPH insulin in Type 2 diabetes
- IQWiG: Short-acting insulin analogues are not superior to regular ‘human’ insulin in Type 2 diabetes
- IQWiG: Rapid-acting analogues are not superior to ‘human’ insulin for Type 1 diabetes
- About IQWiG
- Cochrane review of short-acting insulin analogues versus regular human insulin in patients with diabetes mellitus
- Cochrane review of ‘human’ vs animal insulin
- About Cochrane Reviews
- Insulin – A Voice for Choice By Arthur Teuscher
Zyban – Safety precautions from the Committee on Safety of Medicines
30 May 2002
Zyban is a drug licensed to help people to stop smoking. Since it was first on the market it is estimated that 419,000 people have used Zyban. But the Committee on Safety of Medicines [CSM] have received over 5,000 Yellow card reports of adverse reactions. 126 of these reports were of people having seizures.
The CSM have issued warnings to doctors:
- Changes in the recommended dose
- They have warned that the use of Zyban is contraindicated in people with certain conditions where there is already a risk of seizures.
- They have stated that there are certain conditions where Zyban must NOT be prescribed and these include people treated with oral hypoglycaemic and those treated with insulin. Clearly this means that people with Type 1 and Type 2 diabetes should NOT be prescribed Zyban. They state that the exception to this is where there is compelling clinical justification that the potential benefit of stopping smoking outweighs the increased risk of seizure.for prescribing Zyban.